drugset / Trial / NCT05460429

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

NCT05460429

Phase 4 Unknown 37920 enrolled Sinovac (Dalian) Vaccine Technology Co., Ltd.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of varicella vaccine in healthy children aged 1-6 years with different varicella immunization histories, to evaluate the antibody level of varicella-zoster virus in healthy people aged 0-59 years in Zhejiang Province.

Timeline

Start
2022-07-30
Primary completion
2023-03-15
Completion
2023-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Live Attenuated Varicella Vaccine Vaccine 0.5 ml Intramuscular

Indications